Key result
Deletion/duplication testing followed by direct sequencing detected pathogenic mutations in 98% of males with suspected DMD and 60% with suspected BMD, though sequencing did not improve BMD diagnosis.
Why the study?
Does comprehensive molecular testing including direct sequencing improve the diagnostic yield for Duchenne and Becker muscular dystrophies compared to deletion/duplication testing alone?
Cohort (n=165)
Does comprehensive molecular testing including direct sequencing improve the diagnostic yield for Duchenne and Becker muscular dystrophies compared to deletion/duplication testing alone?
Answers are grounded in this paper and cite their sources.
Direct genomic sequence analysis of the DMD gene improves diagnostic sensitivity for DMD but not for BMD compared to deletion/duplication analysis alone.
Comprehensive molecular testing for mutations in the DMD gene causing Duchenne and Becker muscular dystrophy (DMD/BMD) is challenging because of the large size of the gene and the variety of mutation types. There is an increasing demand for comprehensive DMD gene molecular testing, including deletion/duplication testing of 79 exons and direct sequencing of the 14-kb coding region from genomic DNA, to provide confirmation of clinical diagnoses in affected patients and to determine carrier risk for family members. To determine an efficient strategy to prioritize patients for comprehensive molecular testing of the DMD gene, we tested a consecutive cohort of 165 males referred over a 4-year period because of a suspicion of DMD or BMD using: (1) a new quantitative multiplex polymerase chain reaction (PCR) assay designed to detect deletions or duplications in all exons of the gene and the brain promoter and (2) direct sequencing of the coding region and intron/exon boundaries. For the patients being tested because of a suspicion of DMD, deletion/duplication testing followed by direct sequencing detected pathogenic mutations in 98% (106/108 total patients). However, of the patients tested because of a suspicion of BMD, only 60% (34/57 total patients) had causative mutations identified, all of which were deletions or duplications. Our results suggest that direct genomic sequence analysis of the DMD gene is a useful addition to deletion/duplication testing for diagnosis of DMD, but does not provide an improved sensitivity compared to deletion/duplication analysis alone for the diagnosis of BMD. In addition, due to the relatively common finding of single exon deletions and duplications (22%, 27 of 125 total patients with deletions/duplications), methods to examine all exons of the gene for deletions/duplications should be used as the initial molecular quantitative test for DMD and BMD.
No takes yet. Share an insight, caveat, or question.
Stockley et al. (2006) conducted a cohort in Duchenne and Becker muscular dystrophy (DMD/BMD) (n=165). Deletion/duplication testing and direct sequencing of the DMD gene vs. Deletion/duplication testing alone was evaluated on Detection of pathogenic mutations in patients with suspected DMD. Deletion/duplication testing followed by direct sequencing detected pathogenic mutations in 98% of males with suspected DMD and 60% with suspected BMD, though sequencing did not improve BMD diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: